Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 89, Issue 4, Pages 621-625Publisher
WILEY
DOI: 10.1038/clpt.2011.16
Keywords
-
Categories
Ask authors/readers for more resources
The selective inhibition of sodium-glucose cotransporter 2 (SGLT2) has recently become a focus of potential type 2 diabetes mellitus (T2DM) therapeutics. This review describes the mechanism of SGLT2-induced urinary glucose excretion (UGE) and its effects on parameters of glycemic control in animal models, healthy humans, and patients with T2DM. Key questions on various aspects of the development of SGLT2 inhibitors are discussed, as well as insights regarding this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available